Evaluating 24-h antihypertensive efficacy by the smoothness index: A meta-analysis of an ambulatory blood pressure monitoring database

Journal of Hypertension

Volumn 28, Issue 11, 2010, Pages 2177-2183

  Parati, Gianfranco ^a,b   Schumacher, Helmut ^c   Bilo, Grzegorz ^b   Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

ambulatory blood pressure monitoring; antihypertensive agents; blood pressure; blood pressure variability; smoothness index; telmisartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIAC PATIENT; CARDIOVASCULAR PARAMETERS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; HEMODYNAMICS; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; NEGRO; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; SMOOTHNESS INDEX; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 77958455774     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833e1150     Document Type: Article

References (44)

1. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-h blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5:93-98.
2. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-h blood pressure variability. J Hypertens 1993; 11:1133-1137. (Pubitemid 23307888)
3. Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension 1993; 21:510-524.
4. Mancia G, Omboni S. Ambulatory blood pressure, blood pressure variability and antihypertensive treatment. Clin Exp Hypertens 1996; 18:449-462. (Pubitemid 26148653)
5. ManciaG,OmboniS, Parati G. The importance ofblood pressure variability in hypertension. Blood Press Monit 2000; 5 (Suppl 1):S9-S15.
6. Parati G, Faini A, Valentini M. Blood pressure variability: its measurement and significance in hypertension. Curr Hypertens Rep 2006; 8:199-204.
7. ManciaG,Bombelli M, Facchetti R, MadottoF,Corrao G, Trevano FQ,et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 2007; 49:1265-1270.
8. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G.The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16:1685-1691.
9. Parati G. Blood pressure variability: its measurement and significance in hypertension. J Hypertens 2005; 23 (Suppl 1):S19-S25.
10. Omboni S, Parati G, Mancia G. The trough:peak ratio and the smoothness index in the evaluation of control of 24 h blood pressure by treatment in hypertension. Blood Press Monit 1998; 3:201-204.
11. Rizzoni D, Muiesan ML, Salvetti M, Castellano M, Bettoni G, Monteduro C, et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 2001; 19:703-711.
12. Smith DH, Neutel JM, Lacourcière Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003; 21:1291-1298.
13. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
14. Neutel JM, Kolloch RE, Plouin PF, Meinicke TW, SchumacherH, OTELLOH Study Group. Telmisartan vs. losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension: a randomised ABPM study. J Hum Hypertens 2003; 17:569-575.
15. Neutel JM, Littlejohn TW, Chrysant SG, Singh A, on behalf of the Telmisartan Study Group. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005; 28:555-563.
16. White WB, Punzi HA, Murwin D, Koval SE, Davidai G, Neutel JM. Effects of the angiotensin II receptor blockers telmisartan vs. valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J Clin Hypertens 2006; 8:626-633.
17. Parati G, Omboni S, Malacco E, on behalf of the study group. Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure. Blood Pressure 2006; 15 (Suppl 1):7-17.
18. Mancia G, Parati G, di Rienzo M, Zanchetti A. Blood pressure variability. In: Mancia G, Zanchetti A, editors. Handbook of hypertension: pathophysiology of hypertension. Amsterdam: Elsevier Science; 1997. pp. 117-169.
19. Watson RD, Stallard TJ, Littler WA. Factors determining the variability of arterial pressure in hypertension. Clin Sci 1979; 57 (Suppl 5):283S-285S.
20. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983; 53:96-104.
21. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 2000; 102:1536-1541.
22. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, et al., on behalf of the Syst-Eur investigators. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003; 21:2251-2257.
23. Parati G, Frattola A, Di Rienzo M, Castiglioni P, Pedotti A, Mancia G. Effects of aging on 24 h dynamic baroreceptor control of heart rate in ambulant subjects. Am J Physiol 1995; 268:H1606-H1612.
24. Mancia G, Groppelli A, Casadei R, Omboni S, Mutti E, Parati G. Cardiovascular effects of smoking. Clin Exp Hypertens A 1990; 12:917-929.
25. Groppelli A, Giorgi DAM, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. J Hypertension 1992; 10:495-499.
26. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25:41-46.
27. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637-645.
28. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16 (Suppl 2):S13-S16.
29. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50:560-586.
30. Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3:295-302.
31. Staessen JA, ThijsL, Fagard R,O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282:539-546.
32. Verdecchia P, Schillaci G, Porcellati C. Dippers versus nondippers. J Hypertens 1991; 9 (Suppl):S42-S44.
33. Kario K. Morning surge and variability in blood pressure: a new therapeutic target? Hypertension 2005; 45:485-486. (Pubitemid 40411245)
34. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hara A, et al. Prognostic significance of night-time, early morning, and daytime blood pressure on the risk of cerebrovascular and cardiovascular mortality: the Ohasama study. J Hypertens 2006; 24:1841-1848.
35. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 2000; 36:901-906.
36. Gosse P, Neutel J, Schumacher H, Lacourciere Y, Williams B. Reductions of early morning blood pressure surge with telmisartan compared with ramipril in mild-to-moderate hypertensive patients. J Hypertens 2005; 23 (Suppl 2):S375.
37. Campo C, Saavedra J, Segura J, Roldán C, Ruilope LM, Parati G. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med 2005; 96:365-371.
38. Lindholm LH, Carlberg B, Samuelsson O.Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
39. Mallion JM, Siché JP, Lacourcière Y, and the Telmisartan Blood Pressure Monitoring Group. ABPM comparisonof the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:657-664.
40. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80mg and valsartan 80 mg in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16:1123-1132.
41. Krzesinski JM, Oostvogels L, Schumacher H. The antihypertensive efficacy of telmisartan versus valsartan in patients with mild-to-moderate hypertension after missing one dose. Hypertension 2003; 42 (Suppl 4): 640.
42. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17:347-353.
43. Williams B, Gosse P, Lowe L, Harper R, on behalf of the PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24:193-200.
44. Lacourciere Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19:104-112.